Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight, comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier|||0000-0001-8569-861X
  • Tardón, Guillermo Fernández
  • Alguacil, Juan|||0000-0003-2703-9725
  • Vanaclocha Espí, Mercedes|||0000-0002-7202-2861
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Aragonés, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela|||0000-0001-9242-6364
  • Reguero Celada, Sofía
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m 2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Repisalud
Publicación Artículo científico (JournalArticle)

Toll-Like Receptors in Acute Kidney Injury.

  • Vázquez-Carballo, Cristina
  • Guerrero-Hue, Melania
  • García-Caballero, Cristina
  • Rayego-Mateos, Sandra
  • Opazo-Ríos, Lucas
  • Morgado-Pascual, José Luis
  • Herencia-Bellido, Carmen
  • Vallejo-Mudarra, Mercedes
  • Cortegano, Isabel
  • Gaspar, Maria Luisa
  • Andres, Belen de
  • Egido, Jesús
  • Moreno, Juan Antonio
Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Extracellular Vesicles Enriched in Connexin 43 Promote a Senescent Phenotype in Bone and Synovial Cells Contributing to Osteoarthritis Progression

  • Varela-Eirín, Marta
  • Carpintero-Fernández, Paula
  • Guitián-Caamaño, Amanda
  • Varela Vázquez, Adrián
  • García-Yuste, Alejandro
  • Sánchez-Temprano, Agustín
  • Bravo López, Susana Belén
  • Yáñez-Cabanas, José
  • Fonseca, Eduardo
  • Largo, R
  • Mobasheri, Ali
  • Caeiro, José Ramón
  • Mayán, María D.
[Abstract] The accumulation of senescent cells is a key characteristic of aging, leading to the progression of age-related diseases such as osteoarthritis (OA). Previous data from our laboratory has demonstrated that high levels of the transmembrane protein connexin 43 (Cx43) are associated with a senescent phenotype in chondrocytes from osteoarthritic cartilage. OA has been reclassified as a musculoskeletal disease characterized by the breakdown of the articular cartilage affecting the whole joint, subchondral bone, synovium, ligaments, tendons and muscles. However, the mechanisms that contribute to the spread of pathogenic factors throughout the joint tissues are still unknown. Here, we show for the first time that small extracellular vesicles (sEVs) released by human OA-derived chondrocytes contain high levels of Cx43 and induce a senescent phenotype in targeted chondrocytes, synovial and bone cells contributing to the formation of an inflammatory and degenerative joint environment by the secretion of senescence-associated secretory associated phenotype (SASP) molecules, including IL-1ß and IL-6 and MMPs. The enrichment of Cx43 changes the protein profile and activity of the secreted sEVs. Our results indicate a dual role for sEVs containing Cx43 inducing senescence and activating cellular plasticity in target cells mediated by NF-kß and the extracellular signal-regulated kinase 1/2 (ERK1/2), inducing epithelial-to-mesenchymal transition (EMT) signalling programme and contributing to the loss of the fully differentiated phenotype. Our results demonstrated that Cx43-sEVs released by OA-derived chondrocytes spread senescence, inflammation and reprogramming factors involved in wound healing failure to neighbouring tissues, contributing to the progression of the disease among cartilage, synovium, and bone and probably from one joint to another. These results highlight the importance for future studies to consider sEVs positive for Cx43 as a new biomarker of disease progression and new target to treat OA., This work was supported in part through funding from Health Institute ‘Carlos III’ (ISCIII, Spain), the European Regional Development Fund, ‘A way of making Europe’ from the European Union (to MDM): grant PI19/00145; a grant from the Joint Transnational Call for Proposals for “European Innovative Research & Technological Development Projects in Nanomedicine” EURONANOMED III (AC21_2/00026) (to MDM); a grant from Xunta de Galicia (IN607B2020/12) (to MDM) and from H2020, Future and Emerging Technologies (grant 858014 “PANACHE”) to MDM. MV-E was funded with a predoctoral (ED481A-2015/188) and post-doctoral fellowship (IN606B-2019/004) from Xunta de Galicia. AG-C was funded with a predoctoral fellowship (FIS20/00310) from ISCIII. PC-F was funded with a post-doctoral fellowship and a grant from Xunta de Galicia (INB606B 2017/014 and IN606C 2021/006). We thank members of the CellCOM group for helpful technical suggestion, María Dolores Álvarez Alvariño (CHUS) for generously collecting tissue samples in the operating room after surgery and Arantxa Tabernero (INCYL, University of Salamanca) for kindly providing the human Cx43 plasmid used in this study, Xunta de Galicia; IN607B2020/12, Xunta de Galicia; ED481A-2015/188, Xunta de Galicia; IN606B-2019/004, Xunta de Galicia; INB606B 2017/014, Xunta de Galicia; IN606C 2021/006
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity

  • Varela Vázquez, Adrián
  • Guitián-Caamaño, Amanda
  • Carpintero-Fernández, Paula
  • Carneiro Figueira, Alexander
  • Álvarez, Vanesa
  • Varela-Eirín, Marta
  • Calleja-Chuclá, Teresa
  • Bravo López, Susana Belén
  • Vidal, Anxo
  • Sendón Lago, Juan José
  • Rodríguez-Candela-Mateos, Marina
  • Caeiro, José Ramón
  • Sanz-Moreno, Victoria
  • Aasen, Trond
  • González Blanco, Miguel
  • Sabio, Guadalupe
  • Quindós-Varela, María
  • Rivas, Carmen
  • Santamaría, David
  • Fernández-Lozano, Carlos
  • Fonseca, Eduardo
  • Huertas, Pablo
  • Sánchez-Laorden, Berta
  • Alabert, Constance
  • Mayán, María D.
[Abstract]: BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA damage and cellular senescence. The nuclear compartmentalization promoted by Cx43 contributes to genome instability and synthetic lethality caused by excessive DNA damage, which could provide a therapeutic approach for these tumours to overcome drug resistance. Based on these findings, we designed a drug combination using small extracellular vesicles (sEVs) to deliver the full-Cx43 in combination with the BRAF/MEKi. This study reveals Cx43 as a regulator of DNA repair and BRAF/MEKi response, highlighting the therapeutic potential that this approach could eventually have in the clinic to overcome the limitations of current therapies and improve treatment outcomes for patients with advanced BRAF mutant tumours., This work was supported in part through funding from a grant from Ministry of Science, Innovation and Universities (MICIU/AEI/10.13039/501100011033): PID2022−137027OB-I00 ERDF/EU and a grant from the Joint Transnational Call for Proposals for ‘European Innovative Research & Technological Development Projects in Nanomedicine’ EURONANOMED III (AC21_2/00026) (to M.D.M.); a grant from Xunta de Galicia (IN607B2020/12) (to M.D.M.); a grant from HORIZON-MSCA-2023-SE-01 (101183034) and FET-OPEN-Future and Emerging Technologies (to M.D.M.) and from EU HORIZON-CSA 101079489. TWINFLAG (to M.D.M.). A.V.-V., P.C.-F. and M.V.-E. were funded with post-doctoral fellowship (IN606B 2022/002; INB606B 2017/014 and IN606C 2021/006; IN606B-2019/004) from Xunta de Galicia. A.G.-C. was funded with a predoctoral fellowship (FIS20/00310) from ISCIII. A.C.-F. was funded with a predoctoral fellowship (IN606A 2022/038) from Xunta de Galicia. T.A. acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund (ERDF). V.S.M. was supported by the Institute of Cancer Research; Cancer Research UK (CRUK) C33043/A24478; Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre; Barts Charity; Worldwide Cancer Research 22-0329 and UKRI grant reference EP/X033392., Xunta de Galicia; IN607B2020/12, Xunta de Galicia; IN606B 2022/002, Xunta de Galicia; INB606B 2017/014, Xunta de Galicia; IN606C 2021/006, Xunta de Galicia; IN606B-2019/004, Xunta de Galicia; IN606A 2022/038, United Kingdom. Cancer Research UK (CRUK); C33043/A24478
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Diseño de nuevos materiales fotovoltaicos de banda intermedia

  • Tablero Crespo, César|||0000-0001-9721-1549
  • Wahnón Benarroch, Perla|||0000-0002-5420-2906
  • Palacios Clemente, Pablo|||0000-0001-7867-8880
  • Fernández Sánchez, Julio Juan
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

First principles calculations of electronic structures and metal mobility of NaxSi46 and NaxSi34 clathrates

  • Conesa Cegarra, José Carlos
  • Tablero Crespo, César|||0000-0001-9721-1549
  • Wahnón Benarroch, Perla|||0000-0002-5420-2906
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Development of the exact exchange scheme using a basis set framework

  • Fernández Sánchez, Julio Juan
  • Tablero Crespo, César|||0000-0001-9721-1549
  • Wahnón Benarroch, Perla|||0000-0002-5420-2906
Archivo Digital UPM
Publicación Contribución de congreso (ConferenceOutput)

Intermediate band solar cells and paths towards their implementation by micro and nanotechnologies

  • Luque López, Antonio|||0000-0002-8357-6413
  • Martí Vega, Antonio|||0000-0002-8841-7091
  • Wahnón Benarroch, Perla|||0000-0002-5420-2906
  • Tablero Crespo, César|||0000-0001-9721-1549
  • Cuadra, L.
  • Stanley, C.
  • Glasgow, U.
  • McKee, A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH

  • Bravo, Miren|||0000-0001-5889-9125
  • Raurell, Imma|||0000-0003-4477-7367
  • Hide, Diana
  • Fernández-Iglesias, Anabel|||0000-0003-2364-6675
  • Gil, Mar
  • Barberá Bellés, Aurora|||0000-0002-6201-2643
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Martell, María|||0000-0002-0935-0029
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disorder in developed countries, with the associated clinical complications driven by portal hypertension (PH). PH may precede fibrosis development, probably due to endothelial dysfunction at early stages of the disease. Our aim was to characterize liver sinusoidal endothelial cell (LSEC) dedifferentiation/capillarization and its contribution to PH in NASH, together with assessing statins capability to revert endothelial function improving early NASH stages. Sprague-Dawley rats were fed with high fat glucose-fructose diet (HFGFD), or control diet (CD) for 8 weeks and then treated with simvastatin (sim) (10 mg·kg·day), atorvastatin (ato) (10 mg·kg·day) or vehicle during 2 weeks. Biochemical, histological and hemodynamic determinations were carried out. Sinusoidal endothelial dysfunction was assessed in individualized sorted LSEC and hepatic stellate cells (HSC) from animal groups and in whole liver samples. HFGFD rats showed full NASH features without fibrosis but with significantly increased portal pressure compared with CD rats (10.47 ± 0.37 mmHg vs 8.30 ± 0.22 mmHg; p < 0.001). Moreover, HFGFD rats showed a higher percentage of capillarized (CD32b/CD11b) LSEC (8% vs 1%, p = 0.005) showing a contractile phenotype associated to HSC activation. Statin treatments caused a significant portal pressure reduction (sim: 9.29 ± 0.25 mmHg, p < 0.01; ato: 8.85 ± 0.30 mmHg, p < 0.001), NASH histology reversion, along with significant recovery of LSEC differentiation and a regression of HSC activation to a more quiescent phenotype. In an early NASH model without fibrosis with PH, LSEC transition to capillarization and HSC activation are reverted by statin treatment inducing portal pressure decrease and NASH features improvement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Podocyte and tubular involvement in AngioJet-induced kidney injury

  • Esteras, Raquel
  • Cannata-Ortiz, Pablo
  • del Palacio-Tamarit, Marta
  • Guerrero-Hue, Melania
  • García-Caballero, Cristina
  • Egido, Jesús
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Gracia-Iguacel, Carolina
  • Moreno Gutiérrez, Juan Antonio|||0000-0002-7468-2871
The AngioJet technique combines localized thrombolysis and percutaneous mechanical thrombectomy (PMT). However, PMT may cause acute kidney injury (AKI), which has been ascribed to severe mechanical haemolysis, although no renal biopsies have been reported. We now report the first renal biopsy in a patient with AKI following PMT. There is histological evidence of haemoglobin (Hb)-induced tubular injury and podocyte stress characterized by intracellular Hb and staining for ferritin and hemo-oxygenase-1, suggestive of an adaptive response to oxidative stress. This confirms that Hb is involved in kidney cell injury and supports the existence of several different kidney cellular targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

First joint record of Mesopithecus and cf. Macaca in the Miocene of Europe

  • Alba, David M.|||0000-0002-8886-5580
  • Delson, Eric|||0000-0002-4062-7567
  • Carnevale, Giorgio|||0000-0002-3433-4127
  • Colombero, Simone
  • Delfino, Massimo|||0000-0001-7836-7265
  • Giuntelli, Piero
  • Pavia, Marco|||0000-0002-5188-4155
  • Pavia, Giulio|||0000-0001-8843-3086
Cercopithecid fossil remains from the post-evaporitic Messinian (5.40-5.33 Ma, MN13, latest Turolian, latest Miocene) locality of Moncucco Torinese (Tertiary Piedmont Basin, NW Italy) are described. A talus is assigned to the fossil colobine Mesopithecus pentelicus, while a proximal fragment of ulna and a male lower canine are attributed to cf. Me. pentelicus. An isolated I2 and M3 are assigned to the papionin cf. Macaca sp., and two cercopithecid phalanges are left unassigned even to the subfamily level. The record of Mesopithecus at Moncucco Torinese agrees well with the previously-known range of this species in Italy and elsewhere in Europe, whereas that of cf. Macaca constitutes only the second occurrence of macaques in the Miocene of Eurasia. Although the co-occurrence of these two genera in a single locality had been previously reported in the Pliocene, this is the first instance in which macaques are associated with the Late Miocene M. pentelicus instead of Mesopithecus monspessulanus. The record of cf. Macaca and Mesopithecus-and especially the latter's talar morphology, similar to that of extant arboreal colobines-fits well with paleoenvironmental reconstructions of Moncucco Torinese based on the associated fauna, which indicate a humid and densely-forested environment, probably with more open and drier habitats nearby. From a paleobiogeographic viewpoint, the record of Macaca at Moncucco Torinese, together with the previously reported occurrence at Almenara-Casablanca M (Spain), supports the contention that macaques dispersed from Africa into Europe during the latest Miocene (ca. 5.9-5.3 Ma) at the same time as the sea level drop associated with the Messinian Salinity Crisis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population, The MCC-Spain Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Lope, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Camacho, Antonio
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Villagrasa, Ares|||0000-0003-0928-0427
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Aguilera-Castro, Lara
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan|||0000-0002-1966-1947
  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Biagetti, Betina|||0000-0002-8837-4343
  • Camps-Relats, Laura
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Cocera, Raul
  • Dopazo, Cristina|||0000-0001-6274-5911
  • Fernandez, Andrea
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Jiménez, María M.
  • Jofra Castells, Mariona|||0000-0002-3034-4985
  • Gil, Clara
  • Gómez Gavara, Concepción|||0000-0001-8312-3273
  • Guanozzi, Danila
  • Guevara, Jorge A.
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Malagelada Prats, Carolina|||0000-0001-7097-1492
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Mayorga, Luis
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Pando, Elizabeth|||0000-0001-6898-5502
  • Pérez-Lopez, Ana
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Romero, Alba
  • Tasayco, Staphanie|||0000-0001-7867-349X
  • Vidal-Gonzalez, Judit
  • Vidal Piñeiro, Laura|||0000-0003-3757-3323
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.